236 related articles for article (PubMed ID: 31621900)
1. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma.
Charan M; Dravid P; Cam M; Audino A; Gross AC; Arnold MA; Roberts RD; Cripe TP; Pertsemlidis A; Houghton PJ; Cam H
Int J Cancer; 2020 Jun; 146(11):3184-3195. PubMed ID: 31621900
[TBL] [Abstract][Full Text] [Related]
2. VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.
Englisch A; Altvater B; Kailayangiri S; Hartmann W; Rossig C
Pediatr Blood Cancer; 2020 Oct; 67(10):e28313. PubMed ID: 32729251
[TBL] [Abstract][Full Text] [Related]
3. EZH2 Inhibition in Ewing Sarcoma Upregulates G
Kailayangiri S; Altvater B; Lesch S; Balbach S; Göttlich C; Kühnemundt J; Mikesch JH; Schelhaas S; Jamitzky S; Meltzer J; Farwick N; Greune L; Fluegge M; Kerl K; Lode HN; Siebert N; Müller I; Walles H; Hartmann W; Rossig C
Mol Ther; 2019 May; 27(5):933-946. PubMed ID: 30879952
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
[TBL] [Abstract][Full Text] [Related]
5. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
6. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
7. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
8. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
9. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
10. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.
Davis IJ; McFadden AW; Zhang Y; Coxon A; Burgess TL; Wagner AJ; Fisher DE
Cancer Res; 2010 Jan; 70(2):639-45. PubMed ID: 20068147
[TBL] [Abstract][Full Text] [Related]
11. Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Nan X; Wang J; Cheng H; Yin Z; Sheng J; Qiu B; Lau CC; Yustein JT; Zhao H; Wong STC
Cancer Lett; 2020 Jan; 469():195-206. PubMed ID: 31672491
[TBL] [Abstract][Full Text] [Related]
12. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.
Liu L; Zeng W; Wortinger MA; Yan SB; Cornwell P; Peek VL; Stephens JR; Tetreault JW; Xia J; Manro JR; Credille KM; Ballard DW; Brown-Augsburger P; Wacheck V; Chow CK; Huang L; Wang Y; Denning I; Davies J; Tang Y; Vaillancourt P; Lu J
Clin Cancer Res; 2014 Dec; 20(23):6059-70. PubMed ID: 25231402
[TBL] [Abstract][Full Text] [Related]
13. Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma.
Ban J; Aryee DN; Fourtouna A; van der Ent W; Kauer M; Niedan S; Machado I; Rodriguez-Galindo C; Tirado OM; Schwentner R; Picci P; Flanagan AM; Berg V; Strauss SJ; Scotlandi K; Lawlor ER; Snaar-Jagalska E; Llombart-Bosch A; Kovar H
Cancer Res; 2014 Nov; 74(22):6578-88. PubMed ID: 25281719
[TBL] [Abstract][Full Text] [Related]
14. Preclinical development of a humanized neutralizing antibody targeting HGF.
Kim H; Hong SH; Kim JY; Kim IC; Park YW; Lee SJ; Song SW; Kim JJ; Park G; Kim TM; Kim YH; Park JB; Chung J; Kim IH
Exp Mol Med; 2017 Mar; 49(3):e309. PubMed ID: 28336956
[TBL] [Abstract][Full Text] [Related]
15. Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging.
Liebsch L; Kailayangiri S; Beck L; Altvater B; Koch R; Dierkes C; Hotfilder M; Nagelmann N; Faber C; Kooijman H; Ring J; Vieth V; Rossig C
Br J Cancer; 2013 Aug; 109(3):658-66. PubMed ID: 23839490
[TBL] [Abstract][Full Text] [Related]
16.
Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
[TBL] [Abstract][Full Text] [Related]
17. EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.
Evans CH; Liu F; Porter RM; O'Sullivan RP; Merghoub T; Lunsford EP; Robichaud K; Van Valen F; Lessnick SL; Gebhardt MC; Wells JW
Clin Cancer Res; 2012 Oct; 18(19):5341-51. PubMed ID: 22879388
[TBL] [Abstract][Full Text] [Related]
18. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
[TBL] [Abstract][Full Text] [Related]
19. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
20. CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.
Guerzoni C; Fiori V; Terracciano M; Manara MC; Moricoli D; Pasello M; Sciandra M; Nicoletti G; Gellini M; Dominici S; Chiodoni C; Fornasari PM; Lollini PL; Colombo MP; Picci P; Cianfriglia M; Magnani M; Scotlandi K
Clin Cancer Res; 2015 Jan; 21(1):146-56. PubMed ID: 25501132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
